Dr Doreen Zhu is an Academic Clinical Lecturer based in the Renal Studies Group at the Clinical Trial Service Unit (CTSU) and Oxford Population Health (OxPop) in the University of Oxford, United Kingdom.
She started nephrology and general medicine clinical training in 2016 and was appointed as a Clinical Research Fellow in 2018 for three years. During this time, she completed a MD exploring the associations of blood pressure with kidney outcomes in the Mexico City Prospective Study and worked on the EMPA-KIDNEY trial, which tested whether empagliflozin prevents worsening of kidney disease or deaths from heart disease in people with chronic kidney disease.
For her postdoctoral research, she hopes to study the associations of genetically-predicted risk factors with kidney outcomes and to develop her knowledge and experience of clinical trials, testing new treatments aimed at managing and reducing the progression of chronic kidney disease.
Day 2 - Monday April 15, 2024
Time |
Session |
|
9 a.m.
10:30 a.m.
|
LF03
Magdalena Madero
Chairperson
MexicoChief of Nephrology, Instituto Nacional de Cardiol
PietroRavani
Chairperson
pravani@ucalgary.caCanadaUniversity of Calgary
-
Non-neoplastic Lesions in Nephrectomy Samples: Implications for Kidney Function
-
Understanding the Heterogeneous Trajectory of CKD
MorganGrams
Speaker
morgan.grams@nyulangone.orgUnited StatesNew York University
-
Review of Medical Therapies Proven to Delay CKD Progression
DoreenZhu
Speaker
doreen.zhu@ndph.ox.ac.ukUnited KingdomUniversity of Oxford
-
Impact of Obesity and Novel Treatment Strategies on CKD Progression
PeterRossing
Speaker
DenmarkSteno Diabetes Center Copenhagen
-
Q and A
Hall C4
|